The symptom you describe - strong urge to urinate but little or no urine passes - points to acute urinary retention (AUR). Here is a structured treatment overview:
Acute Urinary Retention: Treatment
What Is It?
AUR is the sudden inability to voluntarily pass urine despite a full bladder and often intense urgency. It is painful in most patients. The most common cause in men is benign prostatic hyperplasia (BPH). Other causes include:
- Urethral stricture
- Medications (opioids, anticholinergics, sympathomimetics)
- Neurologic disease (spinal cord injury, multiple sclerosis, Parkinson's, diabetic neuropathy)
- Post-surgical retention (especially after general/spinal anaesthesia)
- Constipation (worsens or triggers retention)
- Clot obstruction from hematuria
Step 1 - Immediate: Bladder Decompression
Urethral catheterization is the first and most urgent step.
- Standard catheter (14-16F) for most patients
- Coudé (curved-tip) catheter (18-20F) for men with BPH - the curved tip navigates the angulated prostatic urethra; the curved tip should be kept at 12 o'clock during insertion
- Smaller catheter (12-14F) if urethral stricture is suspected (resistance met near the meatus)
- If catheterization fails: urology consult for cystoscopic dilation or suprapubic tube placement (under ultrasound guidance)
If blood clots are causing obstruction, continuous bladder irrigation via a 3-way catheter is needed.
Step 2 - Alpha-1 Blockers (to enable voiding trial)
After catheter placement, the next goal is a Trial Without Catheter (TWOC) - removing the catheter after a few days and seeing if the patient can void spontaneously. About 60% succeed.
Alpha-1 blockers are given to improve TWOC success:
| Drug | Dose | Notes |
|---|
| Tamsulosin | 0.4 mg once daily | Most commonly used; selective for urinary tract |
| Alfuzosin | 10 mg once daily | RCT showed 61.9% vs 47.9% success rate over placebo |
| Doxazosin | 4-8 mg once daily | Less urinary-selective; watch for hypotension |
A meta-analysis of 8 RCTs confirmed alpha-1 blockers significantly increase TWOC success (relative risk 1.55; 95% CI 1.36-1.76) compared to placebo. Duration is typically 1-3 days before catheter removal.
Catheter is usually left in for 3-8 days (median ~5 days) before the voiding trial.
Step 3 - Address the Underlying Cause
| Cause | Management |
|---|
| BPH | Alpha-blocker (immediate); 5-alpha reductase inhibitor (finasteride/dutasteride) for long-term prevention - reduces AUR risk by ~50% but takes months to work |
| Urethral stricture | Urologic dilation or urethroplasty |
| Medications | Taper/stop offending drugs (opioids, anticholinergics) |
| Constipation | Treat aggressively; can directly worsen retention |
| Neurologic cause | Spinal cord compression is an emergency (neurosurgery); others managed with clean intermittent self-catheterization (CIC) every 4-6 hours |
| Infection (UTI) triggered | Appropriate antibiotics |
If TWOC Fails
- Up to three TWOC attempts are reasonable before proceeding to surgery
- Clean intermittent catheterization (CIC) is preferred over indwelling catheter long-term (lower infection risk, may improve bladder function)
- Surgery (e.g., transurethral resection of the prostate - TURP) for refractory BPH cases
After Catheter Removal: Check Post-Void Residual (PVR)
Use a bladder scanner (portable ultrasound) after the voiding trial. A PVR >200 mL suggests risk of recurrence and warrants further management.
Key point: Untreated AUR can cause acute kidney injury from back-pressure on the ureters. Urgent bladder decompression is not optional - it should happen as quickly as possible.
- Campbell Walsh Wein Urology, pp. 4449-4451
- Schwartz's Principles of Surgery, p. 1795-1796